The Enzo Biochem v. Calgene case is significant in patent enablement because it illustrates how courts assess the scope of enablement in biotechnology patents. The MPEP Section 2164.06(b) summarizes the case: “The court held that two patents with claims directed to genetic antisense technology (which aims to control gene expression in a particular organism), were…

Read More